Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-12-03
2010-11-09
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S255000
Reexamination Certificate
active
07829570
ABSTRACT:
The present application is directed to compounds of the formula (I)wherein the substituents are as defined herein, which are useful as kinase inhibitors.
REFERENCES:
patent: 2003/0199525 (2003-10-01), Hirst et al.
Stacker, S.A. et al, Mutations in the V3 Domain of the Cysteine-Knot Motif of Mouse . . . ,(1998), Angiogenesis and Cancer Conference Center, Amer. Assoc. Cancer Res.
Takano et al, Inhibition of Angiogenesis by a Novel Diaminoanthraquinone that Inhibits Protein Kinases C., (1993), Mol. Bio. Cell, vol. 4, pp. 358A.
Taylor E.C. et al, The Synthesis of 4-Aminoisoxazolo [5.4-d] pyrimidines, (1964) Journal of Organic Chemistry, vol. 29(8), pp. 2116-2120.
Terman et al, Identification of a New Endothelial Cell Growth Factor Receptor Tyrosine Kinase, (1991), Oncogene, vol. 6, pp. 1677-1683.
Terman et al, Identification of the KDR Tyrosine Kinase as a Receptor for Vascular . . . , (1992), Biochem. Biophys. Res. Comm., vol. 187(3), pp. 1579-1586.
't Hart et al,Evaluating the validity of animal models for research into therapies for immune-based disorders, (2004) Drug Discovery Today, vol. 9(12), pp. 517-524.
Ulrich et al., Signal Transduction by Receptors with Tyrosine Kinase Activity, (1990), Cell, vol. 61, pp. 203-212.
Williams, Factors regulating the Expression of Vascular Permeability/Vascular Endothelial Growth Factory by Human Vascular Tissues, (1997) Diabetelogia, vol. 40, pp. S118-S120.
Witzenbichler et al, Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue . . . , (1998), Am. J. Pathol., vol. 153(2), pp. 381-394.
Wolff, Burger's Medicinal Chemistry, 5th Edition, Part 1, (1995), pp. 975-977.
Wright et al, inhibition of Angiogenesis In Vitro and In Ovo with an Inhibitor, of Cellular Protein Kinases, MDL 27032, (1992), J. Cellular Phys., vol. 152, pp. 448-457.
Yang et al., Expression and Function of Murine Receptor Tyrosine Linases, TIE and TEK, in Hematopoietic Stem Cells, (1997), Blood, vol. 89(12), pp. 4317-4326.
Yarden et al., Growth Factor Receptor Tyrosine Kinases, (1988), Ann. Rev. Biochem., vol. 57, pp. 443-478.
Achen et al, Vascular Endothellial Growth Factor D (VEGF-D) is a Ligand for the Tyrosine . . . , (1998), Proc. Natl. Acad. Sci. USA, vol. 95(2), pp. 548-553.
4-Anilinoquinazoline Derivatives, (1998), Expert Opin. Ther. Pat., vol. 8(4), pp. 475-478.
Belenkii, L.I. et al, Synthesis of Hheterocycles Based on products of Additon of Polyhaloalkanes to Unsaturated Systems . . . , (1994), Chemical Abstracts, vol. 120(13), pp. 1175.
Brickell et al., The p60 Family of Protein -Tyrosine Kinases: Structure, Regulation, and Function, (1992), Critical Reviews in Oncogenesis, vol. 3(4), pp. 401-446.
Brown et al, Vascular Permeability Factor/Vascular Endothelial . . . , (1997), Regulation of Angiogenesis (ed. L.D. Goldberg and E.M. Rosen), pp. 233-269.
Buchdunger et al., Selective inhibition of the platelet-derived growth factor signa; transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenyloaminopyrimidine class, (1995), Proc. Natl. Acad. Sci. USA, vol. 92, pp. 2558-2562.
Connolly et al, Human Vascular Permeability, (1989), J. Biol. Chem., vol. 264, pp. 20017-20024.
Courtneidge et al., Protein tyrosine kinases, with emphasis on the Src family, (1994), Seminars in Cancer Biology, vol. 5, pp. 239-246.
Cowburn, Peptide Recognition by PTB and PDZ Domains, (1997), Currr. Opin. Struct. Biol., vol. 7(6), pp. 835-838.
Cullinan-Bove et al., Vascular Endothelial Growth Factor/Vascular Permeability Factor Expression in the Rat Uterus: Rapid Stimulation by Estrogen . . . , (1993), Endocrinology, vol. 133(2), pp. 829-837.
De Vries et al, The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor, (1992), Science, vol. 255, pp. 989-991.
Draetta, cdc2 activation: the interplay of cyclin binding and Thr161 phosphorylation, (1993), Trends in Cell Biology, vol. 3, pp. 287-289.
Ducommun et al., cdc2 phosphorylation is required for its interaction with cyclin, (1991), The EMBO Journal, vol. 10 (11), pp. 3311-3319.
Fantl et al, Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules that Mediate Different Signaling Pathways, (1992), Cell, vol. 69, pp. 413-423.
Ferrara et al, The Vascular Endothelial Growth Factor Family of Poly peptides, (1991), J. Cell. Biochem., vol. 47, pp. 211-218.
Ferrara et al, The Biology of Vascular Endothelial Growth Factor, (1997), Endocrine Reviews, vol. 18(1), pp. 4-25.
Isner et al., Angiogenesis and vsculogenesis as therapeutic strategies for postnatal neovscukarization, (1999), The Journal of Clinical Investigation, vol. 103(9), 1231-1236.
Jakeman et al, Developmental Expression of Binding Sites and Messenger Ribnucleic Acid for Vasular Endothelial . . . , (1993), Endocrinology, vol. 133(2), pp. 848-859.
Jellinek et al, Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor, (1994), Biochemistry, vol. 33, pp. 10450-10456.
Kendall & Thomas, Inhibition of Vascular Endothelial Cell Growth Factor Activity by and Endogenously Encoded . . . , (1994), Proc. Natl. Acad. Sci., vol. 90, pp. 10705-10709.
Kim et al, Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumor Growth in vivo, (1993), Nature, vol. 362, pp. 841-844.
Kinsella et al, protein Kinases C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrige, (1992), Exp. Cell. Res., vol. 199, pp. 56-62.
Klagsbrun et al., Vascular Endothelial Growth Factor and its Receptors, (1996), Cytokine & Growth Factor Reviews, vol. 7(3), pp. 259-270.
Koch et al, SH2 and SH3 Domains: Elements that Control Interactions of Cytoplasmic Signaling Proteins, (1991), Science, vol. 252, pp. 668-678.
Kolch et al, Regulation of the Expression of the VEFG/VPS and its Receptors: Rile in Tumor Angiogenesis, (1995), Breast Cancer Research and Treatment, vol. 36, pp. 139-155.
Korpelainen et al., Signaling Angiogenesis and Lymphangiogenesis, (1998), Curr. Opin. Cell Biol., vol. 10, pp. 159-164.
Lees, Cyclin dependent kinase regulation, (1995), Current Opinion in Cell Biology, vol. 7, pp. 773-780.
Lymboussaki et al, Expression of the Vascular Endothelial Growth Factor C Receptor VEGFR-3 in Lymphatic . . . , (1998), Am. J. Pathol., vol. 153(2), pp. 381-394.
Maglione et al, Two Alternative mRNAs Coding for the Angiogenic Factor, Placenta Growth Factor (PIGF), are Transcribed from . . . , (1993), Oncogene, vol. 8, pp. 925-931.
Mariani et al, Inhibition of Angiogenesis by FCE 26806, a Potent Tyrosine Kinase inhibitor, (1994), Proc. Am. Assoc. Cancer Res., vol. 35, pp. 2268.
Matthews et al, A Receptor Tyrosine Kinase cDNA Isolated from a Population of Enriched Primitive Hematopoietic . . . , (1991), Proc. Natl. Acad. Sci. USA, vol. 88, pp. 9026-9030.
Matsushime et al., D-Type Cyclin-Dependent Kinase Activity in Mammalian Cells, (1994), Molecular and Cellular Biology, vol. 14(3), pp. 2066-2076.
Mayo Clinic Staff, Rheumatoid Arthritis, Retrieved from internet Nov. 4, 2004 <http://www.mayoclinic.com/invoke.cfm?id=DS00020&dsection=1>.
Meyer et al, A Novel Vascular Endothelial Growth Factor Encoded by Orf Virus, VEFG-E, Mediates Angiogenesis . . . , (1999), EMBO J., vol. 18(2), pp. 363-374.
Migdal et al, Neuropilin-1 is a Placenta Growth Factor-2 Receptor, (1998), J. Biol. Chem., vol. 273(35), pp. 22272-22278.
Millauer et al, High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis . . . , (1993), Cell, vol. 72, pp. 835-846.
Mustonen et al., Endothelial receptor Tyrosine Kinases Involved in Angiogenesis, (1995), J. Cell Biol., vol. 129(4), pp. 895-898.
Noble et al, Protein Kinase Inhibitors: Insights into Drug Design from Structure, (2004), Science, vol. 303, pp. 1800-1805.
Oelrichs et al, NYK/FLK-1: a Putative Receptor Protein Tyrosine Kinase Isolated From E10 Embryonic Neuroepithelium is Expressed in . . . , Oncogene, vol. 8(1), pp. 11-18, (1993).
Ogawa et al, A Novel Type of Vascular Endothelial Growth Factor, VEGF-E (NZ-7 VEGF), Preferentialy Utilizes . . . , (1998),
Burchat Andrew
Calderwood David J.
Hirst Gavin C.
Ji Zhiqin
Michaelides Michael R.
Abbott Laboratories
Lwicker Kenneth P.
Moore Susanna
O'Brien Gayle B.
Wilson James O
LandOfFree
Substituted 4-amino isoxazolo[5,4-d]pyrimidines as kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 4-amino isoxazolo[5,4-d]pyrimidines as kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 4-amino isoxazolo[5,4-d]pyrimidines as kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4219537